Prognostic factors for visual outcome after intravitreal anti-vegf injection for naive myopic choroidal neovascularization

Retina

Volumn 32, Issue 5, 2012, Pages 949-955

  Yoon, Jong Uk ^a   Kim, Yong Min ^a   Lee, Sung Jun ^b   Byun, Yeo Jue ^a   Koh, Hyoung Jun ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Dongguk University Ilsan Hospital   (South Korea)

Author keywords

intravitreal anti VEGF injection; myopic choroidal neovascularization

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ENDOPHTHALMITIS; EYE; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; LINEAR REGRESSION ANALYSIS; MALE; MULTIVARIATE ANALYSIS; MYOPIA; PROGNOSIS; REFRACTION ERROR; RETINA DETACHMENT; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; VISUAL ACUITY;

EID: 85027937416     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318227aa09     Document Type: Article

References (29)

1. Avila MP, Weiter JJ, Jalkh AE, Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984;91:1573-1581. (Pubitemid 15197032)
2. Yoshida T, Ohno-Matsui K, Ohtake Y, Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups. Ophthalmology 2002;109: 712-719. (Pubitemid 34270128)
3. VIP Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP Report No. 3. Ophthalmology 2003;110:667-673.
4. Lam DS, Chan WM, Liu DT, Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization of pathologic myopia in Chinese eyes: a prospective series of 1-and 2-year follow-up. Br J Ophthalmol 2004;88:1315-1319. (Pubitemid 39312979)
5. Rosenfeld PJ, Brown DM, Heier JS, MARINA Study Group. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
6. Heier JS, Boyer DS, Ciulla TA, FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124: 1532-1542. (Pubitemid 44748725)
7. Brown DM, Kaiser PK, Michels M, et al; for the ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl Med 2006;355: 1432-1444. (Pubitemid 44511558)
8. Ikuno Y, Sayanagi K, Soga K, Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009;147:94-100.
9. Gharbiya M, Allievi F, Mazzeo L, Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009;147:84-93.
10. Chan WM, Lai TY, Liu DT, Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 2009;93: 150-154.
11. Konstantinidis L, Mantel I, Pournaras JA, Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247:311-318.
12. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Intravitreal bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: one year outcome. Br J Ophthalmol 2009; 93:448-451.
13. Yodoi Y Tsujikawa A, Nakanishi H, Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2009;147: 816-824.
14. Yoon JU, Byeon YJ, Koh HJ. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina 2010;30:418-424.
15. Yoshida T, Ohno-Matsui K, Yasuzumi K, Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003; 110:1297-1305. (Pubitemid 36842462)
16. Cohen SY Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina 2009;29:1062-1066.
17. Kojima A, Ohno-Matsui K, Teramukai S, Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2006;244:1474-1479. (Pubitemid 44741259)
18. Bottoni F, Tilanus M. The natural history of juxtafoveal and subfoveal choroidal neovascularization in high myopia. Int Ophthalmol 2001;24:249-255. (Pubitemid 37168157)
19. Axer-Siegel R, Ehrlich R, Weinberger D, Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment. Am J Ophthalmol 2004;138:602-607. (Pubitemid 39420488)
20. Pece A, Vadalà M, Isola V, Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study. Am J Ophthalmol 2007;143:449-454.
21. Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, Photo-dynamic therapy in non-subfoveal choroidal neovasculariza-tion secondary to pathological myopia: 1-year outcome. Br J Ophthalmol 2007;91:1722-1723. (Pubitemid 350207417)
22. Ergun E, Heinzl H, Stur M. Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am J Ophthalmol 2004;138:434-438. (Pubitemid 39208575)
23. Yasuzumi K, Ohno-Matsui K, Yoshida T, Peripapillary crescent enlargement in highly myopic eyes evaluated by fluorescein and indocyanine green angiography. Br J Oph-thalmol 2003;87:1088-1090. (Pubitemid 37064882)
24. Soubrane G, Coscas GJ. Choroidal neovascular membrane in degenerative myopia. In: Ryan SJ, ed. Retina. 4th ed. St Louis, MO: Mosby; 2006:1115-1133.
25. Hirata A, Negi A. Lacquer crack lesions in experimental chick myopia. Graefes Arch Clin Exp Ophthalmol 1998;236:138-145. (Pubitemid 28080515)
26. Gharbiya M, Giustolisi R, Allievi F, Choroidal neovasculari-zation in pathologic myopia: intravitreal ranibizumab versus bevacizumab\a randomized controlled trial. Am J Ophthal-mol 2010;149:458-464.
27. Lai TY, Chan WM, Liu DT, Lam DS. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 2009;29:750-756.
28. Lalwani GA, Rosenfeld PJ, Fung AE, A Varialbe-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 2009;148:43-58.
29. Silva RM, Ruiz-Moreno JM, Nascimento J, Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008;28:1117-1123.